Correction to: Bone Marrow Transplantation (2010) 45, 925–932; doi:10.1038/bmt.2009.272; published online 5 October 2009
Since the publication of the above article, the authors have noticed that the correct conflict of interest statement was not included in their paper. This statement should have read:
Ethics declarations
Competing interests
R de la Cámara, I Jarque, MA Sanz and E Carreras have received honoraria for speaking at the symposia organized on behalf of Pfizer, Merck Sharp & Dohme (MSD), Schering-Plough and Gilead Science. S Grau has received honoraria for speaking at the symposia organized on behalf of Pfizer. RC and MS have sat on the advisory boards on antifungal agents for Pfizer, MSD, Schering-Plough and Gilead Science. EC has sat on the advisory boards on antifungal agents for Pfizer, MSD and Schering-Plough. IJ has sat on the advisory boards on antifungal agents for MSD. MA Casado has served as an external consultant for Schering-Plough SA, and FJ Sabater was an employee of the company at the time of submission.
The authors would like to apologize for any inconvenience caused.
Additional information
The online version of the original article can be found at 10.1038/bmt.2009.272
Rights and permissions
About this article
Cite this article
de la Cámara, R., Jarque, I., Sanz, M. et al. Erratum: Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant 45, 966 (2010). https://doi.org/10.1038/bmt.2009.352
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.352
This article is cited by
-
Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT
Bone Marrow Transplantation (2012)